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Increased expression of T-helper cell activation markers in peripheral blood of 
children with atopic asthma. 
INTRODUCTION 
Asthma is a common and increasingly prevalent 
disease affecting 5% of adults and more than 10% of 
children 1. Although it is one of the most common 
diseases in childhood, its cellular and molecular 
pathology have not been studied frequently in children.  
Original article 
Background: Activated T-helper (CD4) cells have been implicated to 
contribute to the pathogenesis of bronchial asthma. However, the profile of 
circulating CD4 subsets in relation to disease activity and asthma severity is 
unclear. 
Objective: To study the dynamic changes in peripheral blood CD4 cells 
expressing the activation markers naïve/memory (CD45RA/CD45RO) and 
interleukin–2 light chain receptor (CD25) in asthmatic children during and 
after resolution of acute asthma attacks and to determine whether the 
expression of these activation markers would be of value in monitoring asthma 
severity and the response to glucocorticoid inhalation. 
Methods: Peripheral blood samples were obtained from 20 asthmatic children 
aged between 0.5 and 9 years (mean±SD: 4.37±2.37 years) with acute asthma 
attacks, 10 children with lower respiratory tract infection and 20 healthy, age-
matched subjects. CD4 cells expressing CD45RA, CD45RO, CD45RA+RO+ 
and CD25 were analyzed by dual flow cytometry and serum IgE was measured 
by ELISA. In asthmatic children, the measurements were repeated after the 
resolution of acute attacks. 
Results: During acute asthma attacks, the percentages of CD45RA, CD45RO, 
CD45RA+RO+ and CD25 were significantly increased as compared to the 
control group (p<0.05 for CD45RA and <0.0001 for the other 3 subsets). 
After resolution of asthma attacks, a significant reduction of all subsets was 
noticed and the percentages of CD45RA and CD45RO decreased to normal 
values while those of CD45RA+RO+ and CD25 remained significantly higher 
than the controls (p<0.05 for each marker). Unlike healthy children and 
patients with acute lower respiratory infections, asthmatic children showed 
increased CD45RO/CD45RA ratio (>1) and a significant increase of the 
percentage of CD45RA+RO+. During acute asthma attacks, patients with 
severe persistent asthma showed the highest percentages of all T- helper 
subsets when compared to those with moderate or mild persistent asthma. 
Positive correlations were found between serum IgE levels and both CD45RO 
and CD25 (r = 0.962, p<0.001 and 0.882, p<0.05 respectively) during acute 
asthma attacks and these correlations remained significant in remission (r = 
0.632, p<0.05 and 0.589, p<0.05 respectively). Glucocorticoid inhalation 
therapy induced a significant reduction in the percentage of CD45RO, 
CD45RA+RO+ and CD25.  
Conclusion: Peripheral blood T-helper cell activation markers are reliable 
indicators for monitoring disease activity and severity of asthma. The reversed 
ratio of memory/ naïve T-helper cells together with the presence of a clone of 
cells co-expressing both naive and memory surface markers feature atopic 
asthma from acute lower respiratory infections. Glucocorticoid inhalation 
therapy induces a significant inhibition of peripheral blood T-helper cell 
activation markers. 
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In adults, asthma is accompanied by chronic 
inflammation of the bronchial mucosa, in which 
selective eosinophil influx and local T-cell activation 
are characteristic (and almost universal) features 2. It is 
thought that toxic eosinophil products (lipid mediators 
and basic granule proteins) damage the bronchial 
mucosa in asthma, resulting ultimately in the clinical 
manifestations (variable airway obstruction and 
bronchial hyperresponsiveness). Evidence, 
accumulated over the past two decades, suggests that 
selective eosinophil recruitment and activation in 
asthmatic bronchial mucosa is mediated, at least in 
part, by the actions of eosinophil-active cytokines 
derived predominantly from activated CD4 T-cells, of 
which interleukin-5 (IL-5) is uniquely eosinophil-
specific 3,4. 
T-helper cells are a heterogeneous group of cells 
that can be divided into subpopulations on the basis of 
the expression of the cell surface markers. The 
expression of the RA and RO isoforms of the 
leukocyte common antigen (CD45) molecule, define 
two subpopulations. Broadly, CD45RA+ T-cells 
include the “naïve” phenotype and CD45RO+ T cells 
include the “memory” phenotype. Naïve CD4 T cells 
are essential for responses to new foreign antigens and 
have different antigen-presenting cell requirements 
than memory T-cells while memory T cells have in 
vitro recall response to antigens, preferential 
locomotion in response to attractants and mitogens, 
and migrate toward inflammatory sites 5. The in vitro 
studies with human peripheral blood suggest that a 
subset of CD45RA T-helper cells provides helper 
function for IgE synthesis in synergy with the 
CD45RO T-helper cells 6.  
Bronchial biopsy specimens from adults with 
symptomatic asthma revealed increased numbers of 
lymphocytes expressing CD25 (the α chain of IL-2 
receptor), which is suggestive of T-cell activation 2. 
Also, the bronchoalveolar lavage fluid after 
endobronchial segmental allergen challenge showed 
increased numbers of CD4 T-helper cells expressing 
the activation marker CD25 7. Additional evidence of 
T lymphocyte activation was demonstrated by the 
increased expression of CD25 in the peripheral blood 
of adults with acute severe asthma 8.   
Because peripheral blood is the reservoir of the 
lymphocytes that are recruited into the bronchial tree 
during asthma, it is interesting to investigate the profile 
of lymphocyte subsets and T-cell activation in the 
peripheral blood of asthma patients. Although it has 
been reported that activated T-cells were significantly 
increased in the peripheral blood of subjects with 
symptomatic atopic asthma 9, other investigators have 
shown that T-cell activation occurred only within the 
airway 10. The reports in this field contain controversial 
information, and for pediatric asthma, the data are even 
fewer. The relative lack of knowledge about the 
molecular immunopathology of asthma in children 
stems partly from the practical and ethical problems 
with obtaining access to the bronchial mucosa. 
Fortunately, studies on the properties of peripheral 
blood T-cells in adult asthma have suggested that the 
properties of these T-cells, reflect those of cells in the 
bronchial mucosa, owing perhaps to a “spillover” or 
recirculation of the activated T cells into the peripheral 
blood 11. In this study, we used this observation to 
demonstrate the dynamic changes of CD4 cells 
expressing naïve/ memory (CD45RA/CD45RO) and 
the activation marker (CD25) in the peripheral blood of 
asthmatic children during and after resolution of acute 
asthma attacks in order to determine the characteristics 
of T-helper cell activation in atopic asthma and to 
correlate the expression of these markers with asthma 
severity. Also, we studied the changes in the 
expression of activation markers that associate the use 
of inhaled glucocorticoid therapy in asthmatic children. 
 
METHODS 
This case-control study included 20 asthmatic children 
(11 boys and 9 girls) ranging in age from 0.5 to 9 years 
(mean ± SD: 4.37 ±2.37 years) who were followed up 
at the Pediatric Allergy and Immunology Unit of Ain 
Shams University Children’s Hospital, Cairo, Egypt. 
The diagnosis of asthma was established according to 
the American Thoracic Society criteria 12. These 
patients were evaluated during acute asthma attacks 
and followed up until the attacks subsided clinically 
and were then reevaluated. The asthma exacerbations 
were triggered by exposure to food allergens in 12 
children, upper respiratory tract infections in 2, and 
both factors together in 3 subjects. In three patients the 
triggering agent was not clear. The patients were sub-
classified into 6 patients with mild persistent, 7 with 
moderate persistent, and 7 with severe persistent 
asthma according to clinical data and peak expiratory 
flow (PEF) measurements 13; the latter was measured 
in cooperative children older than 5 years.  
At entry of the study, all patients were receiving 
inhaled B2 agonists “as required”; while 9 patients 
were on regular oral B2 agonist (dosage: 0.1-0.3 
mg/kg/day) and 12 patients were taking regular sodium 
cromoglycate inhalation (30-40mg/day). 
The age-and sex- matched control group 
comprised 20 healthy children (10 boys, 10 girls) 
ranging in age between 0.75 to 9 years (4.18 ±2.64 
years). These children had no personal or family 
histories of asthma or allergic diseases. In addition, 10 
non-asthmatic non-atopic children (6 boys, 4 girls) 
from one to 7 years of age (3.6 ±1.8 years) with acute 
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lower respiratory tract infections were enrolled in the 
study for comparison. These patients had no personal 
or family histories of asthma or other allergic 
disorders, and were life-long free of asthma symptoms 
and their chest auscultation findings as well as chest 
radiographic images were consistent with the diagnosis 
of bronchiolitis in 2 patients, lobar pneumonia in 3, 
and bronchopneumonia in 5 patients.  
An informed consent was obtained from the 
parents of each child before enrollment.   
 
Study Design 
All asthmatic children underwent detailed history 
taking and medical examination in order to determine 
the degree of asthma severity and the severity of the 
attack. Patients who were maintained on regular 
inhaled and/or oral corticosteroids were excluded from 
the study. At this stage, peripheral blood samples were 
obtained and medications were subscribed according to 
asthma severity. All recruited asthmatic patients were 
commenced or continued B2 agonist inhalation and 
sodium cromoglycate. Owing to the severity of 
bronchospasm, 15 patients started de novo inhaled 
corticosteroid therapy at dosages ranging from 100 to 
300ug/day. All children were followed up clinically 
until remission was achieved and a second blood 
sample was then obtained from each patient. The 
interval between the first and second sample ranged 
from 7 to 14 days. 
Peripheral blood sampling, detailed history and 
medical examination were performed only once on the 
healthy controls and those with acute lower respiratory 
tract infection.  
 
Methods 
Five milliliters (5ml) of venous blood were collected 
from each subject under aseptic conditions and were 
divided into: (i) Three ml were dispensed gently into a 
tube containing K-EDTA as anticoagulant (1mg/ml) 
and were used immediately for complete blood 
counting, differential counting (using Coulter counter 
T660 -Coultronics, France) and flow cytometric 
analysis.  (ii) Two ml were collected into a plain tube 
to obtain serum used for the determination of 
immunoglobulin (Ig) E level. Sera collected were kept 
frozen at –20ºC till analysis. 
 
Flow cytometric analysis 
Optimal dilutions of antibodies labeled with either 
fluorescein isothiocyanate (FITC) or phycoerythrin 
(PE) were used. Labeled antibodies under study were 
CD4-FITC, CD4-PE, CD45RO-PE, CD45RA-FITC 
and CD25-PE (Becton- Dickinson, San Jose, CA, 
USA). Negative isotype-matched controls FITC and 
PE labeled were used to determine the non-specific 
binding of monoclonal antibodies. 
Red cells in EDTA samples were lysed using 
whole blood lysing technique (ammonium chloride 1.5 
mmol/L, potassium biphosphate 100 mmol/L, and tetra 
sodium EDTA 10 mmol/L). The total leukocyte count 
(TLC) was adjusted in each sample to 5-10x103 cell/μl. 
One hundred μl of each sample were added to 
corresponding tubes containing 10 μl of each of the 
monoclonal antibodies studied for comparison. This 
was followed by gentle vortex and incubation in the 
dark for 15 minutes. Two ml of working lysing 
solution were added to each tube, vortexed and 
incubated again in the dark for 5-10 minutes, 
centrifuged at 3000 rpm for 5 minutes and the 
supernatant was discarded. Tubes were then washed 3 
times with phosphate buffered saline (PBS) and lastly 
cells were resuspended in 500 μl of PBS and analyzed 
using Coulter Epics XL flow cytometer (Profile 
Instrument, Coulter electronics, Hielach, FL, USA). 
Lymphocytes were electronically gated using light 
scatter parameters (forward and side scatter). The 
results were expressed as percentage of cells positively 
coexpressing the predetermined markers in comparison 
to isotype matched controls. 
 
Estimation of serum IgE levels 
Immunoglobulin E in stored serum samples was 
measured by enzyme linked immunosorbent assay 
(ELISA) (Pathozyme-IgE, Omega Diagnostics 
Limited, UK). The value of IgE used for data analysis 
was the percentage from the highest normal for age 13 




Comparisons among studied groups were made by 
Student’s t test for normally distributed data and 
Mann-Whitney U-test for non-parametric data. Paired 
data were analyzed by paired t test. Correlation 
coefficients and their statistical significance were 
determined with Spearman’s rank correlation analysis. 
Statistica for Windows version 5 (Stat software, Tulsa, 
Ok, USA) was used for all statistical analyses. 




T helper cell subsets in the studied groups 
As shown in table 1, the percentages of CD45RA, 
CD45RO, CD45RA+RO+, and CD25 in patients with 
acute asthma attacks were significantly increased as 
compared to control children (P<0.05 for CD45RA and 
<0.0001 for the other 3 subsets). Also, the percentages 
of CD45RA+RO+ and CD25 during acute asthma 
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attacks were higher than those of children with lower 
respiratory tract infections (P<0.0001 for each subset). 
After the acute attacks had resolved by therapy, the 
percentages of CD45RA and CD45RO became 
comparable to those of normal controls while those of 
CD45RA+RO+ and CD25 were still significantly 
higher than normal ranges (P<0.005, <0.05 
respectively). The analyses with paired t test showed a 
significant reduction of the percentages of CD45RA, 
CD45RO, CD45RA+RO+, and CD25 cells when 
patients were in remission (P<0.05 for CD45RA and 
<0.0001 for the other 3 subsets).  
Concerning patients with lower respiratory tract 
infections, a significant increase in the proportion of 
CD45RA and CD45RO cells as compared to normal 
children was observed (P<0.0001 and <0.05 
respectively). Meanwhile, no significant differences in 
the percentages of CD45RA+RO+ and CD25 were 
found between both groups. 
When the distribution from naïve to memory T-
helper cells was analyzed by means of calculating the 
RO/RA ratio, patients with lower respiratory infections 
showed RO/RA ratio that was comparable with the 
control ratio (<1) while a reversed RO/RA ratio (>1) 
was seen in asthmatic children.  
 
 
Table (1): The percentages of peripheral blood T-Helper (CD4) cells expressing naïve 
(RA)/memory (RO) and interleukin–2 light chain receptor (CD25) in the studied groups 
 
% Of CD4 T-cell 
Expressing 
Asthma (n:20) 






        Range 
        Mean ± SD 
               Paired t     
               Z 
             ●Z  
 
10.5 - 69.5                          12.5 - 50.8 
36.56 ± 19.77                     25.67 ± 9.81 
                         2.418 * 
2.326*                                1.217    
1.539                                  4.0034* 
 
41.7 - 59.7 





17 - 33.5 
22.36 ± 4.97 
 
CD45RO 
        Range 
        Mean ± SD 
               Paired t 
               Z 
             ●Z 
 
13.5 - 81.7                           5.49 - 24.2 
37.17 ± 25.48                      12.82 ± 5 
                       4.809** 
4.341**                               1.0008  
1.363                                   4.09* 
 
15.6 - 21.3 





10.7 - 20.8 
13.72 ± 2.81 
CD45RO/RA ratio 
        Range 
        Mean ± SD 
              Paired t 
              Z  
           ●Z 
 
0.465 - 2.585                     0.509 - 0.789 
1.05 ± 0.52                        0.509 ± 0.133 
                        4.619** 
3.029*                               2.569  
4.339**                             2.903*  
 
0.261- 0.462 




0.367 - 0.914 
0.63 ± 0.16 
CD45RA+RO+ 
        Range 
        Mean ± SD 
              Paired t 
              Z  
           ●Z 
 
11.9 - 79.8                          0.16 - 49.2 
45.19 ± 22.93                     13.19 ± 15.53 
                       7.598**  
5.41**                                3.029* 
4.339**                              2.463*  
 
0.6 - 3.1 





1.2 - 4.1 
2.24 ± 0.78 
CD25 
        Range 
        Mean ± SD 
              Paired t 
              Z  
           ●Z 
 
5.21- 49.1                          5.57 - 20.4 
24.5 ± 13.97                       6.66 ± 4.21 
                      7.021** 
6.255**                            1.961* 
6.443**                            1.561  
 
2.1- 6.7 




1.68 - 6.8 
4.25 ± 1.47 
LRI: Lower respiratory tract infection. 
Mann-Whitney test was employed, Z: Vs controls, ●Z: Vs LRI  
*: Significant (P<0.05), **: Highly significant (P<0.0001). 
 
 
T helper subsets and asthma severity 
During attacks of acute asthma, patients with severe 
persistent asthma showed the highest percentages of all 
studied T helper subsets (CD45RA, CD45RO, 
CD45RA+RO+ and CD25) when compared to those 
with moderate or mild persistent asthma. However, 
after resolution of the acute attacks, the percentages of 
CD45RO and CD25 were still significantly elevated in 
severe persistent asthma when compared with the other 
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Table (2): The mean percentages of peripheral blood T-helper (CD4) cells expressing naïve (RA) / memory 
(RO) and interleukin–2 light chain receptor (CD25) according to asthma severity. 
 
Mean % of CD4 
cells expressing  
Mild (n: 6) 
M ± SD 
Moderate  (n: 7) 
M ± SD              t value 
Severe (n: 7) 



















23.46 ± 7.28 
 
14.61 ± 0.82  
 
14.82 ± 3.06 
 
7.15 ± 2.11 
 
 
24.0 ± 5.85 
 
9.98 ± 2.29 
 
3.35 ± 4.63 
 
3.99 ± 1.35 
 
 
29.71 ± 18.28       0.781 
 
25.88 ± 6.35         4.285* 
 
48.47 ± 7.41         10.335** 
 
24.37 ± 2.71         12.59** 
 
 
21.45 ± 6.68          0.722 
 
10.59 ±3.96           0.33 
 
9.45 ± 7.12            1.79 
 
5.09 ± 2.12            1.08 
 
54.62 ± 15.88       4.404*        2.721* 
 
67.78 ± 16.23       7.96**         6.357** 
 
67.92 ± 7.98        15.27**       4.725* 
 
39.5 ± 6.62          15.27**       5.59* 
 
 
31.32 ± 13.06      1.263           1.77 
 
17.49 ± 4.45        3.711*         3.058* 
 
25.36 ± 20.25      2.589*          1.961 
 
10.49 ± 4.8          3.188*          2.718* 
Student t- test was employed, t: versus mild, ●t: versus moderate.  
*: Significant (P<0.05); **: Highly significant (P<0.0001) 
 
 
Figure 1: A set of histograms that represent flow cytometric analysis of the percent (%) 
coexpression of T cell surface markers in an asthmatic patient understudy. The first one (A) 
shows gating of lymphocytes depending on forward (FS) and side scatters (SS). In the second 
histogram (B), quadrants are set on the basis of negative controls. Percent of coexpression is 
represented on the upper right quadrant, % expression of FITC labeled markers on lower right 
quadrant, and % expression of PE labeled markers on upper left quadrant. Histograms “C” 
through “F” show coexpression of different markers in succession CD45RA+ CD4+ (47.5%), 
CD45RO+CD4+ (20.8%), CD45RO+CD45RA+ (46.1%), and CD4+CD25+ (11.6%). 
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Correlation analyses 
Positive correlations were found between T helper 
cells expressing CD45RO and those expressing CD25 
in patients with acute asthma attack (r = 0.873,P<0.05) 
and in remission (r = 0.873, P<0.05). 
The co-expression of naïve/memory surface 
markers (CD45RA+RO+) on T helper cells was 
positively correlated with CD45RO and CD25 cells 
during asthma attacks (r = 0.797, P<0.05 and 0.902, 
P<0.001 respectively) and in remission (r = 0.722, 
P<0.05 and 0.840, P<0.001 respectively). A strong 
positive correlation was found between the percentage 
of T helper cells expressing the CD45RO and serum 
IgE levels during acute asthma attacks (r = 0.962, 
P<0.001). This correlation remained significant during 
remission (P< 0.05). A similar positive correlation was 
also seen between serum IgE values and the percentage 
of T helper cells expressing CD25 in patients with 
acute asthma attacks (r = 0 .882,P<0.05) and during 
remission (r = 0.589, P<0.05) (Figure 2). Meanwhile, 
the eosinophil percentage in the peripheral blood of 
asthmatic patients did not show any significant 
correlation with either CD45RO or CD25 during 
asthma attack (r = 0.346, P>0.05 and 0.371, P>0.05 
respectively) or in remission (r = 0.266, P>0.05 and 
0.316, P>0.05 respectively).   
 
Effect of glucocorticoid inhalation on the peripheral 
blood T-helper cell subsets 
In asthmatic children, the introduction of 
glucocorticoid inhalation therapy was associated with a 
significant reduction in the mean percentages of 
peripheral blood T cells expressing CD45RO, 
CD45RA+RO+ and CD25 (Figure 3). 
 




















0 10 20 30 40 50 60 70 80 90



















4 8 12 16 20 24 28




















0 10 20 30 40 50 60























































Figure 2: Positive correlations were found between the percentages of 
peripheral blood memory T-helper cells (CD45RO) and serum IgE (% of 
normal) among asthmatic children during acute attacks (A) and after resolution 
(B). Also, similar relationships were found between the percentages of 
peripheral blood interleukin–2 light chain receptor (CD25) and serum IgE (% of 
normal) during acute attacks of asthma (C) and in remission (D). 
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Figure 3: Percentages of peripheral blood CD4 cells expressing the activation markers CD45RA, 
CD45RO, CD45RARO and CD25 in atopic asthmatic children at the beginning of the study 
(before) and after introduction of inhaled glucocorticoid therapy (after). P values by paired t test. 




In this study, using dual flow cytometry, we examined 
the kinetics of CD4 cells expressing CD45RA, 
CD45RO, CD45RA+RO+ and CD25 surface 
molecules in asthmatic children during and after 
resolution of acute asthma attacks that developed 
spontaneously in response to allergen exposure. Our 
results revealed that the percentages of these surface 
markers in the peripheral blood of children with acute 
asthma attacks were significantly higher than those of 
healthy subjects. Previous studies reported increased 
expression of CD45RO and CD25 on T-helper cells in 
both atopic and non-atopic asthmatics as compared to 
their respective controls 14-16. Also, the increased 
expression of CD25 on the T-helper cells was shown to 
correlate positively with the levels of plasma soluble 
interleukin-2 receptor in acute asthma attacks 17. 
Moreover, our results showed significant reduction in 
the percentages of CD45RA, CD45RO, CD45RARO 
and CD25 after resolution of asthma attacks denoting 
that the expression of these activation markers was up-
regulated during acute exacerbation of asthma. The 
remarkable decrease of the peripheral blood T-helper 
cell activation markers after resolution of acute asthma 
attacks might be due to the potential homing tendency 
of memory T cells (CD45RO) to the bronchial mucosa 
of atopic patients during remission 18, and to the nature 
of IL-2Rα (CD25), which is expressed upon T cell 
activation and fades away when cells return to the 
resting state 17. However, it is worth mentioning that 
during remission the percentages of CD45RA+RO+ 
and CD25 were still higher than those of the controls 
denoting that after resolution of asthma attack there 
might be some degree of T-helper cell stimulation that 
signals an ongoing subclinical allergic lung 
inflammation.  
The concurrent lower respiratory tract infections in 
bronchial asthma are often impossible to distinguish 
from spontaneous exacerbations of asthma 7.  The 
question of whether or not the presence of airway 
inflammation in asthma would increase the activation 
markers of T-helper cells was of major interest to us. 
For this purpose, we included ten patients with lower 
respiratory tract infection in whom the diagnosis of 
atopic asthma was ruled out by medical history, chest 
auscultation and radiographic findings. Among these 
patients, the expression of CD45RA and CD45RO on 
T-helper cells were significantly elevated as compared 
to healthy children and were comparable to those with 
acute attacks of asthma. In view of the fact that the RA 
isoform of CD45 is expressed on newly formed T cells 
that have not encountered specific antigen while during 
activation by exposure to specific antigen, the RA 
isoform is stably modulated to RO 19, the observed 
elevation in the expression of CD45RA and CD45RO 
in patients with lower respiratory tract infections could 
be due to pathogen-induced stimulation of T-helper. 
Consequently, one might suggest that the increased 
expression of CD45 RA and CD45RO during asthma 
would be due to the ongoing inflammation rather than 
being an inherent feature of atopy. In fact, this 
suggestion was refuted when the distribution of T-
helper cell activation marker from RA to RO was 
further analyzed and a reversed RO/RA ratio (>1) was 
seen in asthmatic children as compared to those with 
acute lower respiratory infections and the control 
subjects. The possible explanation of this finding relies 
on the fact that in normal non- atopic individuals, the 
naive T-helper cell (CD45RA) switches upon 
activation to memory cells (CD45RO), and because the 
rate of apoptosis of the RO isoform is faster than that 
of the RA isoform 20 the uniformity of RO/RA ratio is 
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always kept <1. According to our findings, the 
reversed RO/RA ratio in atopic subjects might 
represent a state of increased T-helper cell activation 
that is accompanied by decreased rate of memory cell 
(CD45RO) apoptosis.  
Another important finding in this study was the 
isolation of a clone of T-helper cells that co-expressed 
both RA and RO isoforms of CD45. Although, the 
exact function of cells expressing both isoforms is 
unknown, yet it has been suggested that these cells are 
transitional cells progressing from naïve to memory 
phenotypes or from resting to recently primed cells 18. 
Also, in vitro studies have shown that the transition 
from CD45RA to CD45RO is accompanied by cell 
activation and proliferation 21. Compatible with this 
view, our data showed that the mean percentage of T-
helper cells expressing both isoforms was 45.19% 
during acute asthma attacks and declined significantly 
to 13.19% after the resolution of asthma, the latter 
percentage was still significantly higher than that of 
healthy children (2.24%) and those with lower 
respiratory tract infections (2.07%). Therefore, we 
suggest that the observed increase of T-helper cells 
expressing both RA and RO isoforms might reflect the 
hyperactivity and the dynamic nature of T-helper cell 
in atopic asthma. This suggestion was further 
consolidated by the significant positive correlation 
found between the percentages of CD4 cells expressing 
both isoforms and those expressing either CD45RO or 
CD25 in asthmatic children.  
Studies conducted on lung biopsies and 
bronchoalveolar lavage fluids of patients with atopic 
asthma have shown significant numbers of activated T- 
helper cells (CD25) following allergen challenge 
indicating that the degree of T-helper cell activation is 
positively correlated with the degree of broncho-
spasm2,22. Also, peripheral blood CD25 T-helper cell 
counts were positively correlated with the increase in 
airway obstruction in patients with severe asthma 7,8. 
Moreover, our results showed that the degree of T-
helper cell activation was influenced by the frequency 
of asthma attacks (asthma severity) since the 
percentages of CD45RO, CD45RARO and CD25 were 
significantly elevated among cases with severe 
persistent asthma as compared to the corresponding 
values observed in those with moderate and with mild 
persistent asthma. These observations denote that the 
rate of T-helper cell activation reflects both the 
severity and frequency of bronchospasm. 
Elevated IgE in serum is one of the most important 
events in the pathogenesis of atopic asthma. It has been 
reported that in atopy, the stimulated memory T-helper 
cells (CD45RO) provide contact-dependent activation 
signal to B cells to induce IgE switching via secretion 
of IL-13 23. In our study, the serum IgE values 
correlated positively with the percentage of T-helper 
cells expressing CD45RO in asthmatic patients during 
acute attacks of asthma and in remission. Also, similar 
to others 16, our results revealed a significant positive 
correlation between the percentages of CD25 and 
serum IgE in atopic asthmatic children denoting that T 
cell activation is associated with increased IgE 
production.   
It is well known that eosinophils also, play an 
important role in the inflammation of the airway in 
asthma. In addition, T-helper 2 lymphocytes stimulated 
by specific allergens secrete IL-5 that induces 
proliferation, and prolonged survival of eosinophils 4. 
In addition, several groups reported a positive 
correlation between activated memory CD4 T cells and 
the percentage of eosinophils in bronchoalveolar 
lavage fluid of asthmatics after bronchial allergen 
challenge2,24,25. Contrary to what was expected, the 
peripheral blood eosinophil percentages did not 
correlate significantly with either CD45RO or CD25 
percentages in the peripheral blood. This might be due 
to the recruitment of eosinophil to the bronchial 
mucosa during exacerbation of asthma 2,7,22, or because 
the eosinophils stimulated by cytokines have a longer 
survival time 4 unlike the transient expression of the 
activation markers on T-helper lymphocytes.  
Glucocorticoids are the most effective therapy for 
the control of asthma symptoms and reversal of 
bronchial hyperresponsiveness. Previous studies have 
suggested that they do this, at least partly, by reducing 
T cell activation and concomitant cytokine production 
15,26. In addition, inhaled glucocorticoids reduce the 
expression of the activation markers in both T 
lymphocytes recovered from bronchoalveolar lavage 
and peripheral blood, along with improvement of 
symptoms27,28. In this study, among the 15 patients 
who achieved clinical remission by inhaled 
glucocorticoid therapy, the expression of T-helper cell 
activation markers decreased significantly after 
treatment, though not reaching values of healthy 
children. Of note, the majority of these patients had 
either moderate or severe persistent asthma, thus, the 
possibility that the sustained expression of T-helper 
stimulation markers was influenced by asthma severity 
cannot be ruled out. This lends an additional support to 
the concept that the alteration of T-helper cell 
stimulation is an inherent feature of asthma and current 
therapies may alleviate the clinical manifestations of 
acute bronchospasm but do not induce complete down 
regulation of T-helper stimulation. Therefore, we 
suggest that monitoring of T-helper cell activation 
markers during therapy would provide some 
knowledge about the degree of control of T-helper cell 
activity. In clinical practice, this would help in the 
adjustment of glucocorticoid inhalation therapy, 
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especially during quiescence of asthma symptoms, in 
order to provide proper control of subclinical lung 
inflammation with consequent airway remodeling.   
In conclusion, peripheral blood T-helper cell 
activation markers are reliable indicators for 
monitoring disease activity and severity of asthma. The 
reversed ratio between naïve and memory T-helper 
cells together with the presence of a clone of T-helper 
cells co-expressing both naive and memory isoforms 
characterize atopic asthma from acute respiratory 
infections. Glucocorticoid inhalation therapy induces a 
significant inhibition of T-helper cell hyperactivity in 
childhood atopic asthma.   
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